###begin article-title 0
###xml 33 37 33 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nos2</italic>
Inducible nitric oxide synthase, Nos2, does not mediate optic neuropathy and retinopathy in the DBA/2J glaucoma model
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 187 190 <span type="species:ncbi:10116">rat</span>
###xml 313 316 <span type="species:ncbi:10116">rat</span>
###xml 542 547 <span type="species:ncbi:10090">mouse</span>
Nitric oxide synthase 2 (NOS2) contributes to neural death in some settings, but its role in glaucoma remains controversial. NOS2 is implicated in retinal ganglion cell degeneration in a rat glaucoma model in which intraocular pressure (IOP) is experimentally elevated by blood vessel cauterization, but not in a rat glaucoma model where IOP was elevated by injection of hypertonic saline. To test the importance of NOS2 for an inherited glaucoma, in this study we both genetically and pharmacologically decreased NOS2 activity in the DBA/2J mouse glaucoma model.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 18 23 18 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nos2 </italic>
###xml 167 172 167 172 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nos2 </italic>
###xml 224 229 224 229 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nos2 </italic>
###xml 334 339 334 339 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nos2 </italic>
###xml 257 261 <span type="species:ncbi:10090">mice</span>
###xml 321 325 <span type="species:ncbi:10090">mice</span>
###xml 370 374 <span type="species:ncbi:10090">mice</span>
###xml 465 469 <span type="species:ncbi:10090">mice</span>
The expression of Nos2 in the optic nerve head was analyzed at both the RNA and protein levels at different stages of disease pathogenesis. To test the involvement of Nos2 in glaucomatous neurodegeneration, a null allele of Nos2 was backcrossed into DBA/2J mice and the incidence and severity of glaucoma was assessed in mice of each Nos2 genotype. Additionally, DBA/2J mice were treated with the NOS2 inhibitor aminoguanidine and the disease compared to untreated mice.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 17 22 17 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nos2 </italic>
###xml 286 291 286 291 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nos2 </italic>
###xml 387 392 387 392 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nos2 </italic>
###xml 359 363 <span type="species:ncbi:10090">mice</span>
Optic nerve head Nos2 RNA levels varied and increased during moderate but decreased at early and severe stages of disease. Despite the presence of a few NOS2 positive cells in the optic nerve head, NOS2 protein was not substantially increased during the glaucoma. Genetic deficiency of Nos2 or aminoguanidine treatment did not alter the IOP profile of DBA/2J mice. Additionally, neither Nos2 deficiency nor aminoguanidine had any detectable affect on the glaucomatous optic nerve damage.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 170 175 170 175 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nos2 </italic>
###xml 41 45 <span type="species:ncbi:10090">mice</span>
Glaucomatous neurodegeneration in DBA/2J mice does not require NOS2 activity. Further experiments involving various models are needed to assess the general importance of Nos2 in glaucoma.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 64 65 64 65 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 66 67 66 67 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 237 238 237 238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 283 284 283 284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 285 286 285 286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 347 348 347 348 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 349 350 349 350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 468 470 468 470 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 471 473 471 473 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 56 62 <span type="species:ncbi:9606">people</span>
###xml 675 683 <span type="species:ncbi:9606">patients</span>
Glaucoma affects the vision of approximately 70 million people [1,2]. Optic nerve head excavation and degeneration of retinal ganglion cells (RGCs)are unifying characteristics of glaucoma. The causes of glaucoma are diverse and complex [3]. Many risk factors are known for glaucoma [3-5], with elevated intraocular pressure (IOP) being prominent [4-9]. IOP can be pharmacologically lowered, which in some cases can inhibit the development and progression of glaucoma [10-12]. However, in a significant number of cases, decreasing IOP does not prevent glaucoma progression. Identifying and targeting the mechanisms of RGC degeneration could help to protect the vision of more patients. Unfortunately, the molecular mechanisms of glaucoma are not well understood, and currently no therapies that target the neurodegeneration are commonly employed in clinical practice.
###end p 11
###begin p 12
###xml 89 93 89 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nos2</italic>
###xml 108 111 108 111 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nos</italic>
###xml 113 117 113 117 <italic xmlns:xlink="http://www.w3.org/1999/xlink">iNos</italic>
###xml 267 269 267 269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 270 272 270 272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 388 390 388 390 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 391 393 391 393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 532 534 532 534 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 708 710 708 710 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
Nitric oxide has different roles in the central nervous system. Nitric oxide synthase 2 (Nos2; or inducible Nos, iNos) can be induced in response to a variety of external signals. In some settings, NOS2 activity plays an important role in inducing neurodegeneration [13,14]. Nitric oxide production, particularly through NOS2, has been implicated in ischemia-induced death in the retina [15-18]. The ability of a NOS2 inhibitor to protect RGCs from ischemia led to the suggestion that NOS2 inhibition may be protective in glaucoma [18]. The possibility that NOS2 inhibition could be neuroprotective in glaucoma was strengthened by a report showing that NOS2 inhibition delays RGC degeneration after axotomy [19].
###end p 12
###begin p 13
###xml 198 200 198 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 201 203 201 203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 286 288 286 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 289 291 289 291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 393 395 393 395 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 432 434 432 434 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 608 610 608 610 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 706 707 706 707 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 788 790 788 790 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 791 793 791 793 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 117 125 <span type="species:ncbi:9606">patients</span>
###xml 307 312 <span type="species:ncbi:9606">human</span>
###xml 502 506 <span type="species:ncbi:10116">rats</span>
###xml 625 628 <span type="species:ncbi:10116">rat</span>
Several lines of evidence point to a possible role for NOS2 in mediating glaucomatous neurodegeneration. In glaucoma patients, NOS2 expression was found to be up-regulated in optic nerve head glia [20-22]. The optic nerve head is believed to be an important site of damage in glaucoma [23-30]. In addition, human optic nerve head astrocytes can be induced to express NOS2 by either cytokines [22] or increased hydrostatic pressure [31]. NOS2 is induced in astrocytes of the optic nerve head in eyes of rats that have had intraocular pressure artificially increased by cauterization of the extraocular veins [32]. In the same rat model of glaucoma, pharmacological inhibition of NOS2 by aminoguanidine or L-N(6)-(1-iminoethyl)lysine 5-tetrazole amide reduced the number of RGCs that died [33,34].
###end p 13
###begin p 14
###xml 144 146 144 146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 147 149 147 149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 289 292 <span type="species:ncbi:10116">rat</span>
###xml 395 400 <span type="species:ncbi:10090">mouse</span>
The general importance of NOS2 in glaucoma was recently questioned by studies that do not support a role for NOS2 in another model of glaucoma [35,36]. Thus, the general importance of NOS2 induction for glaucoma is not certain. Considering these conflicting results from different induced rat models of glaucoma, it is important to further test the potential involvement of NOS2 in an inherited mouse model of glaucoma.
###end p 14
###begin p 15
###xml 247 249 247 249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 250 252 250 252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 448 450 448 450 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 451 453 451 453 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 664 666 664 666 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 768 770 768 770 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 869 871 869 871 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 872 874 872 874 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 927 929 927 929 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 1059 1061 1059 1061 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 1062 1064 1062 1064 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 1155 1157 1155 1157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 11 16 <span type="species:ncbi:10090">mouse</span>
###xml 153 158 <span type="species:ncbi:9606">human</span>
###xml 265 270 <span type="species:ncbi:10090">mouse</span>
###xml 658 662 <span type="species:ncbi:10090">mice</span>
###xml 712 716 <span type="species:ncbi:10090">mice</span>
###xml 863 867 <span type="species:ncbi:10090">mice</span>
###xml 1375 1380 <span type="species:ncbi:9606">human</span>
###xml 1425 1429 <span type="species:ncbi:10090">mice</span>
The DBA/2J mouse develops an inherited glaucoma with IOP elevation that is secondary to a pigment dispersing iris disease. DBA/2J glaucoma is similar to human glaucomas in that it is age-related and the pressure elevation is natural and variable [37-41]. The DBA/2 mouse has become one of the most widely used glaucoma models. The pressure elevation often leads to massive RGC loss, with the majority of eyes losing greater than 90% of their RGCs [40,42]. Reported differences in the timing and nature of neuron death in DBA/2 substrains point to a complex disease process that is affected by environmental as well as genetic differences between colonies of mice [40]. In our well characterized colony of DBA/2J mice, RGCs are specifically vulnerable to the glaucoma [28]. The pattern of RGC death supports involvement of axon injury in the optic nerve of DBA/2J mice [28,43] as well as in a closely related strain, DBA/2NNia [44]. In fact, detailed studies of the optic nerve support early injury of RGC axons as a key pathologic feature of DBA/2 glaucomas [45,46], with experimental evidence for an insult(s) damaging axons within the optic nerve head [45]. Considering the complex disease etiology, the specific vulnerability of RGCs, the characteristic pattern of RGC death and the early axon damage in the optic nerve head, DBA/2J glaucoma has important similarities to human glaucoma. For these reasons, we used DBA/2J mice in the current study. We used both genetic ablation and pharmacological inhibition of NOS2activity to test the involvement of NOS2 in glaucomatous damage to the optic nerve and retina in this inherited glaucoma model.
###end p 15
###begin title 16
Results
###end title 16
###begin title 17
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS2 </italic>
NOS2 expression during DBA/2J glaucoma
###end title 17
###begin p 18
###xml 9 11 9 11 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 12 14 12 14 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 15 17 15 17 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 40 42 40 42 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 43 45 43 45 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 46 48 46 48 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 75 80 75 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nos2 </italic>
###xml 201 206 201 206 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nos2 </italic>
###xml 516 521 516 521 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nos2 </italic>
###xml 603 608 603 608 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nos2 </italic>
###xml 678 680 678 680 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A</xref>
###xml 1025 1027 1025 1027 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B</xref>
###xml 1141 1143 1141 1143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1C</xref>
###xml 104 112 <span type="species:ncbi:9606">patients</span>
###xml 117 120 <span type="species:ncbi:10116">rat</span>
###xml 216 220 <span type="species:ncbi:10090">mice</span>
###xml 896 900 <span type="species:ncbi:10090">mice</span>
In some [19-22,32] but not all studies [35,36,47], increased expression of Nos2 is reported in glaucoma patients and rat models of glaucoma. To determine the temporal and spatial expression pattern of Nos2 in DBA/2J mice, we examined RNA and protein levels in the optic nerve head at different stages of glaucoma. The optic nerve head extending from the vitreal surface to approximately the non-myelinated-myelin junction of the optic nerve was dissected and used for RNA preparation. There was a modest increase of Nos2 RNA by quantitative real time PCR analysis in eyes with moderate axon damage, but Nos2 levels appeared to be lower in eyes with early or severe damage (Fig. 1A). Immunohistochemical analysis of sagittal sections did not detect NOS2 protein in either the retina or optic nerve head in the majority of eyes at each stage of disease. As a positive control, kidney sections from mice treated with lipopolysaccahride (LPS) were immunoreacted with the NOS2 antibody and NOS2 positive cells were detected (Fig. 1B). Rare cells that were NOS2 positive were identified in the optic nerve head of two severely affected eyes (Fig. 1C). Although these expression studies provided no clear association between NOS2 and glaucoma, NOS2 is a powerful modulator of cell functions that may be transiently expressed by single cells. Therefore, we continued to test the role of NOS2 in this glaucoma by both genetically and pharmacologically inhibiting its function.
###end p 18
###begin p 19
###xml 0 43 0 43 <bold xmlns:xlink="http://www.w3.org/1999/xlink">NOS2 expression during glaucoma progression</bold>
###xml 46 47 46 47 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 66 71 66 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nos2 </italic>
###xml 117 122 117 122 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nos2 </italic>
###xml 544 549 540 545 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nos2 </italic>
###xml 765 766 761 762 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 1001 1002 997 998 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C</bold>
###xml 246 250 <span type="species:ncbi:10090">mice</span>
###xml 359 363 <span type="species:ncbi:10090">mice</span>
###xml 1081 1085 <span type="species:ncbi:10090">mice</span>
NOS2 expression during glaucoma progression. (A) Optic nerve head Nos2 RNA expression. Relative expression levels of Nos2 at different stages of glaucoma were determined using DeltaCT ratios (see Methods). 'Control' eyes from 4 months old DBA/2J mice were considered to be pre-glaucomatous and showed no axon damage. 'Sample' eyes from 10.5 months old DBA/2J mice were assessed for glaucomatous axon damage and grouped into the no or early, moderate or severe stages of damage (see Methods). Values given are relative to pre-glaucoma controls. Nos2 expression was variable within each disease group (indicated by the SEM bars). Overall it decreased comparing pre-glaucoma with no or early glaucoma and increased modestly in eyes with moderate glaucoma (p < 0.05). (B) NOS2 protein localization in LPS-treated kidney (above) and no primary control (below). The NOS2 antibody shows strong and specific NOS2 staining (Red) in LPS-treated kidneys, with no non-specific binding of the secondary antibody. (C) NOS2 protein localization in the optic nerve heads of 10.5 months old DBA/2J mice, with the lower panels showing higher magnification of the boxed regions. There was no obvious correlation between NOS2 localization and glaucoma progression, although rare NOS2 positive cells were seen in eyes with severe glaucoma (arrow). All sections were processed, stained and imaged under identical conditions. The images shown here are representative of three different sections from three different eyes with the three different stages of glaucoma. Bars = 75 mum.
###end p 19
###begin title 20
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS2 </italic>
###xml 57 61 <span type="species:ncbi:10090">mice</span>
NOS2 deficiency does not alter the IOP profile of DBA/2J mice
###end title 20
###begin p 21
###xml 34 38 34 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nos2</italic>
###xml 57 62 57 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nos2 </italic>
###xml 63 67 63 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nos2</italic>
###xml 67 69 67 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tm</italic>
###xml 70 74 70 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lau </italic>
###xml 67 74 67 74 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>tm</italic>1<italic>Lau </italic></sup>
###xml 88 90 88 90 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 189 194 189 194 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nos2 </italic>
###xml 460 462 460 462 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 463 465 463 465 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 466 468 466 468 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 519 524 519 524 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nos2 </italic>
###xml 657 662 657 662 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nos2 </italic>
###xml 782 787 782 787 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nos2 </italic>
###xml 849 850 849 850 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 941 942 941 942 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 274 278 <span type="species:ncbi:10090">mice</span>
###xml 838 842 <span type="species:ncbi:10090">mice</span>
###xml 857 861 <span type="species:ncbi:10090">mice</span>
###xml 1000 1004 <span type="species:ncbi:10090">mice</span>
To investigate the involvement of Nos2, a null allele of Nos2 (Nos2tm1Lau [Nos2tm1Lau; [48]]) was backcrossed into the DBA/2J strain for greater than 13 generations. The genetic removal of Nos2 ensures that there is no enzymatic activity throughout life. Glaucoma in DBA/2J mice is the result of elevated IOP that is secondary to an iris disease. Preventing or lessening the iris disease alleviates IOP elevation and prevents the subsequent neurodegeneration [38,49,50]. Therefore, it is necessary to determine whether Nos2 genotype altered the iris disease or IOP profile. Slit lamp examination at various time points throughout the experiment showed that Nos2 genotype had no affect on the age of onset, progression, or severity of the iris disease (data not shown). Importantly, Nos2 genotype did not alter IOP in either young or aged mice (Fig. 2), and mice of all genotypes had a glaucomatous IOP elevation at 10-11 months of age (Fig. 2, P < 0.001, ANOVA, for all comparisons compared to young mice).
###end p 21
###begin p 22
###xml 0 34 0 34 <bold xmlns:xlink="http://www.w3.org/1999/xlink">NOS2 deficiency does not alter IOP</bold>
###xml 408 411 406 409 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nos</italic>
###xml 411 415 409 413 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 434 437 430 433 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nos</italic>
###xml 437 441 433 437 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 460 463 454 457 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nos</italic>
###xml 463 467 457 461 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 536 539 528 531 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nos</italic>
###xml 539 543 531 535 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 562 565 552 555 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nos</italic>
###xml 565 569 555 559 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 588 591 576 579 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nos</italic>
###xml 591 595 579 583 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 61 65 <span type="species:ncbi:10090">mice</span>
NOS2 deficiency does not alter IOP. The IOP distributions of mice of each genotype overlap extensively. The boxes show the upper and lower quartiles and the bars show the extremes including outliers. The centerline of each diamond is the mean with the upper and lower points of each diamond representing the 95% confidence intervals of the mean. Mean +/- s.e.m in mm Hg, number of eyes examined; 3.5 months, Nos+/+ 12.6 +/- 0.24, 18; Nos+/- 11.9 +/- 0.30, 19; Nos-/- 12.2 +/- 0.19, 19; P value for all comparisons > 0.08; 10-11 months, Nos+/+ 21.9 +/- 0.87, 39; Nos+/- 21.0 +/- 0.95, 32; Nos-/- 23.6 +/- 1.3, 30, P value for all comparisons >0.09.
###end p 22
###begin title 23
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS2 </italic>
NOS2 deficiency does not prevent glaucomatous neurodegeneration
###end title 23
###begin p 24
###xml 109 111 109 111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 355 363 355 363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3C, D, E</xref>
###xml 596 598 596 598 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3E</xref>
###xml 30 34 <span type="species:ncbi:10090">mice</span>
###xml 210 214 <span type="species:ncbi:10090">mice</span>
###xml 312 316 <span type="species:ncbi:10090">mice</span>
###xml 555 559 <span type="species:ncbi:10090">mice</span>
Some optic nerves from DBA/2J mice begin to show signs of glaucomatous neurodegeneration at 9 months of age [40]. The incidence and severity of glaucoma then increases rapidly over the next months, but not all mice develop glaucomatous nerve damage. Complete deficiency of NOS2 did not prevent homozygous mutant mice from developing severe glaucoma (Fig. 3C, D, E), showing that NOS2 is not required for glaucomatous axon degeneration in the optic nerve. Additionally, NOS2 deficiency did not lessen the amount of glaucomatous optic nerve degeneration in mice that were 10-12 months of age (Fig. 3E).
###end p 24
###begin p 25
###xml 0 61 0 61 <bold xmlns:xlink="http://www.w3.org/1999/xlink">NOS2 deficiency does not alter glaucomatous neurodegeneration</bold>
###xml 64 68 64 68 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A, B</bold>
###xml 127 131 127 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nos2</italic>
###xml 131 135 131 135 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 136 137 136 137 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 143 147 143 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nos2</italic>
###xml 147 151 147 151 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 152 153 152 153 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 164 165 164 165 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C</bold>
###xml 258 262 258 262 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nos2</italic>
###xml 262 265 262 265 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 269 270 269 270 <bold xmlns:xlink="http://www.w3.org/1999/xlink">D</bold>
###xml 356 360 356 360 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nos2</italic>
###xml 360 364 360 364 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 398 399 398 399 <bold xmlns:xlink="http://www.w3.org/1999/xlink">E</bold>
###xml 401 406 401 406 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nos2 </italic>
###xml 643 647 643 647 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nos2</italic>
###xml 647 651 647 651 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 660 664 660 664 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nos2</italic>
###xml 664 668 664 668 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 677 681 677 681 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nos2</italic>
###xml 681 685 681 685 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 709 713 709 713 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nos2</italic>
###xml 713 717 713 717 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 729 733 729 733 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nos2</italic>
###xml 733 737 733 737 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 749 753 749 753 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nos2</italic>
###xml 753 757 753 757 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 802 805 802 805 <bold xmlns:xlink="http://www.w3.org/1999/xlink">F) </bold>
###xml 846 851 846 851 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nos2 </italic>
###xml 1022 1027 1022 1027 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nos2 </italic>
###xml 1263 1268 1263 1268 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nos2 </italic>
###xml 1309 1313 1309 1313 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nos2</italic>
###xml 1313 1316 1313 1316 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 1333 1337 1331 1335 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nos2</italic>
###xml 1337 1340 1335 1338 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 1357 1361 1353 1357 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nos2</italic>
###xml 1361 1364 1357 1360 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 1491 1495 1485 1489 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nos2</italic>
###xml 1495 1499 1489 1493 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 1505 1509 1499 1503 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nos2</italic>
###xml 1509 1513 1503 1507 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 1520 1524 1514 1518 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nos2</italic>
###xml 1524 1528 1518 1522 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 212 216 <span type="species:ncbi:10090">mice</span>
###xml 851 855 <span type="species:ncbi:10090">mice</span>
###xml 1221 1225 <span type="species:ncbi:10090">mice</span>
NOS2 deficiency does not alter glaucomatous neurodegeneration. (A, B) There were no gross anatomical differences between young Nos2+/+ (A) and Nos2-/- (B) nerves. (C) Eventually 80% of the optic nerves of DBA/2J mice develop severe optic nerve degeneration (Nos2+/+). (D) The complete absence of NOS2 did not prevent glaucomatous neurodegeneration as many Nos2-/- nerves had severe axonal damage. (E) Nos2 genotype had no effect on the distribution of nerve damage. Numbers of nerves by age, genotype and disease state were: (given as total number analyzed, genotype, number of that genotype with mild, moderate, severe glaucoma) 3.5 months 6 Nos2+/+ 6,0,0; 7 Nos2+/- 7,0,0;11 Nos2-/- 11,0,0; 10-12 months 53 Nos2+/+ 23,3,27; 53 Nos2+/- 21,9,23; 56 Nos2-/- 17,3,36 (P value for all comparisons > 0.3). F) Average counts of RGC layer neurons from Nos2 mice of each genotype with either severe glaucomatous damage or no detectable glaucomatous damage (total number of cells of the 8 fields counted per retina; see methods). Nos2 genotype conferred no differential protective effect to RGCs in eyes with different degrees of axon loss. RGCs comprise 45-50% of cells in the RGC layer [71] and so almost all RGCs were lost in mice with severe axon loss independent of Nos2 genotype. Percentage of surviving cells; Nos2+/+, 54.4% +/- 1.5; Nos2+/-, 54.6% +/- 1.5; Nos2-/-, 58.0% +/- 2.5; P values for all comparisons > 0.28. Number of retinal flat mounts counted, (given as genotype, mild, severe) Nos2+/+ 9, 7; Nos2+/- 12, 8; Nos2-/- 8, 13. Bar = 100 mum.
###end p 25
###begin p 26
###xml 313 315 313 315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 509 514 509 514 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nos2 </italic>
###xml 652 654 652 654 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3F</xref>
###xml 573 577 <span type="species:ncbi:10090">mice</span>
###xml 846 850 <span type="species:ncbi:10090">mice</span>
Although NOS2 deficiency did not affect axon degeneration, it is a formal possibility that it may affect apoptosis of the RGC somata. We have previously shown that BAX deficiency (BAX is a potent regulator of apoptosis) prevents somal apoptosis even when almost all RGC axons have degenerated in the optic nerve [42]. To assess if NOS2 deficiency protects RGC somata, even though it has no affect on their axons, we counted RGC layer cells for eyes whose nerves demonstrated different degrees of axon damage. Nos2 genotype had no affect on the number of RGC layer cells in mice with either 'no or early' or severe glaucomatous optic nerve damage (Fig. 3F). Thus, NOS2 deficiency does not differentially protect the RGC somata. Overall, our genetic studies detected no beneficial affect of completely removing NOS2 activity in glaucomatous DBA/2J mice.
###end p 26
###begin title 27
Aminoguanidine Treatment
###end title 27
###begin p 28
###xml 123 125 123 125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 202 205 <span type="species:ncbi:10116">rat</span>
###xml 756 760 <span type="species:ncbi:10090">mice</span>
The lack of detectable protective affect of genetically ablating NOS2 contrasts with the report of Neufeld and colleagues [51], who found that the NOS2 inhibitor aminoguanidine was neuroprotective in a rat model with induced IOP elevation. The outcome of these genetic and pharmacological studies may differ for a variety of reasons, including the possibility that the chemical inhibitor is not completely specific and has unknown off-target effects that may affect outcome. To better understand our findings in light of these reports, and to assess whether aminoguanidine has off-target effects that protect against glaucoma by a mechanism that is independent of NOS2, we tested the ability of aminoguanidine treatment to alleviate the glaucoma of DBA/2J mice.
###end p 28
###begin p 29
###xml 201 205 <span type="species:ncbi:10090">mice</span>
###xml 239 243 <span type="species:ncbi:10090">mice</span>
###xml 368 372 <span type="species:ncbi:10090">mice</span>
###xml 395 399 <span type="species:ncbi:10090">mice</span>
###xml 573 577 <span type="species:ncbi:10090">mice</span>
###xml 805 809 <span type="species:ncbi:10116">rats</span>
###xml 816 819 <span type="species:ncbi:10116">rat</span>
Starting at either 3 or 5 months of age (2 different experiments), aminoguanidine (Ag) was administered in drinking water (1 mg/ml). Water consumption was measured for 50 Ag-treated and 50 non-treated mice, to determine the dose of Ag the mice received and whether Ag in the drinking water affected water consumption. Aminoguanidine did not affect the amount of water mice consumed (non-treated mice 4.0 +/- 0.3 ml/day and Ag-treated 3.9 +/- 0.2 ml/day; P = 0.736) nor did it affect their body weight even after being on the drug for 6 months (average g +/- SEM, number of mice; control, 35.2 +/- 1.0, 50; Ag-treated, 35.4 +/- 0.9, 51; p = 0.89). This level of water consumption resulted in a calculated dose of 110 mg/kg/day. This dose is similar to that achieved by Neufeld and colleagues in their aged rats (mean rat body weight 0.575 kg, daily consumption 60 mg, dose 104 mg/kg/day).
###end p 29
###begin title 30
Aminoguanidine treatment does not alter IOP
###end title 30
###begin p 31
###xml 403 405 403 405 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 406 408 406 408 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 593 595 593 595 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4A</xref>
###xml 677 679 677 679 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 680 682 680 682 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 189 193 <span type="species:ncbi:10090">mice</span>
###xml 212 216 <span type="species:ncbi:10090">mice</span>
###xml 431 435 <span type="species:ncbi:10090">mice</span>
###xml 482 486 <span type="species:ncbi:10090">mice</span>
Ag-treatment did not change the time course or the severity of the iris disease (data not shown). We first checked for any affect of Ag-treatment on IOP using young pre-glaucomatous DBA/2J mice. The IOP of young mice was not altered by Ag-treatment from 2 to 3.5 months of age. Similarly long-term Ag-treatment had no affect on IOP when assessed at 10 to 11 months, key ages of elevation in both sexes [39,40]. The IOPs of treated mice were significantly elevated compared to young mice (P < 0.001). Importantly, Ag-treatment did not alter the average IOP or the population distribution (Fig. 4A). The lack of effect of Ag-treatment on IOP is consistent with previous studies [35,51].
###end p 31
###begin p 32
###xml 0 77 0 77 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Aminoguanidine treatment does not alter IOP or glaucomatous neurodegeneration</bold>
###xml 79 83 79 83 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(A) </bold>
###xml 476 477 466 467 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 146 150 <span type="species:ncbi:10090">mice</span>
###xml 933 937 <span type="species:ncbi:10090">mice</span>
Aminoguanidine treatment does not alter IOP or glaucomatous neurodegeneration. (A) Ag-treatment did not affect the pre-glaucomatous IOP of DBA/2J mice (3.5 months: average mmHg +/- s.e.m., number of eyes examined; control 11.8 +/- 0.2, 19; Ag-treated 11.7 +/- 0.2, 23; P = 0.76). Ag-treatment did not affect the ocular hypertension during the key window in disease progression, between 10 and 11 months (control, 18.2 +/- 1.0, 31; Ag-treatment, 16.6 +/- 1.3, 30; P = 0.334). (B) Ag-treatment from 5 months of age does not alter glaucomatous neurodegeneration (given as total number analyzed, treatment group, number of that treatment with mild, moderate, severe glaucoma) 10 months, 51 controls, 22,6,23; 51 Ag-treated 21,6,25; P = 0.293; 11.5 months, 55 controls, 18,6,31; 46 Ag-treated, 16,7,23, P = 0.896. (C) Ag-treatment beginning at 3 months of age does not protect from glaucomatous neurodegeneration. Nine months old treated mice actually tended to have more severe damage (given as total number analyzed, treatment group, number of that treatment with mild, moderate, severe glaucoma) 9 months, 42 controls, 27,7,8; 41 Ag-treated 17,6,18; P = 0.04; 10 months, 43 controls, 10,1,32; 49 Ag-treated, 6,2,41, P = 0.4; 11 months, 43 controls, 4,3,36; 37 Ag-treated, 5,3,29, P = 0.8. The experiments shown in B and C were performed at different institutions (see text).
###end p 32
###begin title 33
Aminoguanidine treatment is not effective at preventing glaucomatous neurodegeneration
###end title 33
###begin p 34
###xml 185 187 185 187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4B</xref>
###xml 602 604 602 604 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4C</xref>
###xml 968 970 968 970 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 971 973 971 973 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 974 976 974 976 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
###xml 52 56 <span type="species:ncbi:10090">mice</span>
###xml 227 231 <span type="species:ncbi:10090">mice</span>
###xml 366 370 <span type="species:ncbi:10090">mice</span>
###xml 378 382 <span type="species:ncbi:10090">mice</span>
###xml 515 519 <span type="species:ncbi:10090">mice</span>
###xml 962 966 <span type="species:ncbi:10090">mice</span>
When treatment was started at 5 months of age using mice housed at The Jackson Laboratory, Ag-treatment did not alter the distribution of nerve damage at either 10 or 11.5 months (Fig. 4B; p > 0.2 for both ages). In fact, many mice developed severe glaucoma despite Ag-treatment. This lack of protection was confirmed with a second experiment using large cohorts of mice. These mice were housed and treated at Alcon Laboratories. The Ag treatment was the same except that it commenced at 3 months of age. For these mice, glaucomatous optic nerve damage was assessed at 9, 10 and 11 months of age (Fig. 4C). At no time point did Ag protect from degeneration, and at 9 months it tended to exacerbate the disease (P = 0.04). Interestingly, the damage was more severe in the second experiment. This fits with the variability of disease between different reports from different institutions and suggests that environmental factors alter disease progression in DBA/2J mice [40,44,52]. Overall, our combination of genetic and pharmacologic experiments provides no evidence for a role of NOS2 in this model of glaucoma.
###end p 34
###begin title 35
Discussion
###end title 35
###begin p 36
###xml 345 347 345 347 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 348 350 348 350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 500 502 500 502 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 503 505 503 505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 506 508 506 508 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 509 511 509 511 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 679 684 679 684 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nos2 </italic>
###xml 1181 1183 1181 1183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B53">53</xref>
###xml 182 190 <span type="species:ncbi:9606">patients</span>
###xml 477 480 <span type="species:ncbi:10116">rat</span>
###xml 1245 1250 <span type="species:ncbi:10090">mouse</span>
Deciphering the mechanisms responsible for RGC dysfunction and demise in glaucoma is expected to lead to new neuroprotective treatments that will help to preserve the vision of more patients. NOS2 can be induced in nervous system microglia and astrocytes during disease, and NOS can act as an important mediator of neural cell damage and death [13,14]. NOS2 was reported to be induced in optic nerve glia during glaucoma, and involved in glaucomatous damage to the retina in a rat model of glaucoma [20-22,33,51]. Here we tested the involvement of NOS2 in glaucomatous neurodegeneration using the inherited DBA/2J model of glaucoma. There were modest changes in optic nerve head Nos2 RNA expression during the various stages of disease progression. Occasionally, NOS2 protein was detected in optic nerve cells with advanced glaucoma but not in unaffected optic nerves. However, neither the complete genetic ablation nor the treatment with an inhibitor of NOS2 had any affect on the severity or incidence of this glaucoma. Although our studies have not assessed if other nitric oxide synthases could have compensated for the absence of NOS2, as has been suggested in other systems [53], our results do not support a damaging role of NOS2 in this mouse model of glaucoma. We clearly demonstrate that glaucoma can manifest even when NOS2 is completely absent.
###end p 36
###begin p 37
###xml 149 151 149 151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 152 154 152 154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 155 157 155 157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 158 160 158 160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 161 163 161 163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 164 166 164 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B54">54</xref>
###xml 167 169 167 169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B56">56</xref>
###xml 366 368 366 368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 369 371 369 371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 416 418 416 418 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 553 555 553 555 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 780 782 780 782 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 783 785 783 785 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 341 346 <span type="species:ncbi:9606">human</span>
###xml 356 364 <span type="species:ncbi:9606">patients</span>
###xml 382 385 <span type="species:ncbi:10116">rat</span>
###xml 498 503 <span type="species:ncbi:9606">human</span>
###xml 528 533 <span type="species:ncbi:9606">human</span>
###xml 585 588 <span type="species:ncbi:10116">rat</span>
In contrast to our results, Neufeld and colleagues have proposed an important role for NOS2 in glaucoma and suggested its inhibition as a treatment [21,22,31-34,51,54-56]. These studies have provided a variety of data supporting a role for NOS2 in glaucomatous neurodegeneration. They have shown that NOS2 is expressed in the optic nerve in human glaucoma patients [20-22] and in a rat model of ocular hypertension [32]. NOS2 expression can be induced by increased hydrostatic pressure in cultured human astrocytes derived from human optic nerve heads [31]. Most intriguingly, using a rat model where IOP is artificially elevated by cauterization of extraocular veins, Neufeld and colleagues have shown that pharmacological inhibition of NOS2 could lessen glaucomatous RGC death [33,51].
###end p 37
###begin p 38
###xml 31 33 31 33 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 202 204 202 204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B57">57</xref>
###xml 671 673 671 673 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 715 716 715 716 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 836 838 836 838 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 140 144 <span type="species:ncbi:10116">rats</span>
###xml 417 420 <span type="species:ncbi:10116">rat</span>
###xml 477 485 <span type="species:ncbi:9606">patients</span>
###xml 556 560 <span type="species:ncbi:10116">rats</span>
###xml 618 622 <span type="species:ncbi:10116">rats</span>
Recently, Pang and colleagues [35] did not find evidence for a role of NOS2 in glaucomatous neurodegeneration. They induced elevated IOP in rats by injection of hypertonic saline into episcleral veins [57]. No significant increase in NOS2 expression (at the protein or message level) was found in optic nerve head cells due to ocular hypertension. Furthermore, they found no evidence for increased NOS2 in transected rat optic nerve heads or in optic nerve heads from glaucoma patients. Aminoguanidine treatment had no affect on glaucomatous damage in the rats. Also using episcleral injection of hypertonic saline in rats to induce elevated IOP, Kasmala and colleagues [36] found that another inhibitor of NOS2, L-N(6)-(1-iminoethyl)lysine 5-tetrazole (which has been shown to be protective in the vessel cauterization glaucoma model [33]) did not protect RGCs from death induced by elevated intraocular pressure.
###end p 38
###begin p 39
###xml 272 274 272 274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 985 987 985 987 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B58">58</xref>
###xml 988 990 988 990 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B59">59</xref>
###xml 1256 1258 1256 1258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 693 697 <span type="species:ncbi:10116">rats</span>
###xml 1250 1254 <span type="species:ncbi:10116">rats</span>
There are multiple possible explanations for the differences in the observed role of NOS2 in glaucoma in these studies, including differences in genetically determined risk factors between the animals that were used. Pang and colleagues discuss many of the possibilities [35]. Here we limit discussion to a known difference between the studies of Neufeld and colleagues (which implicate NOS2) and other studies (which detected no effect of NOS2). Neufeld and colleagues cauterize extraocular veins to induce high IOP. This approach is more traumatic to vessels and surrounding tissue than the injection of hypertonic saline into extraocular veins (the method used by the other groups studying rats). The DBA/2J model is natural and does not involve experimentally-induced trauma to vessels. The greater vascular trauma in the cauterization model may somehow affect experimental outcome. It has been suggested that the extraocular vein cauterization method may induce retinal ischemia [58,59]. If true, ischemia could contribute significantly more to RGC death in the cauterization model than in the other models. NOS2 is clearly involved in ischemic retinopathy and NOS2 inhibitors (including aminoguanidine) can protect RGCs from ischemic injury in rats [16]. It will be important to assess ischemic markers in the various models to help determine if ischemia is more severe in the cauterization model and if this explains the differential efficacy of NOS2 inhibition.
###end p 39
###begin p 40
###xml 124 125 124 125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 126 128 126 128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B58">58</xref>
###xml 129 131 129 131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B60">60</xref>
###xml 657 659 657 659 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B61">61</xref>
###xml 660 662 660 662 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B63">63</xref>
###xml 1005 1007 1005 1007 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B64">64</xref>
###xml 1008 1010 1008 1010 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B65">65</xref>
###xml 114 122 <span type="species:ncbi:9606">patients</span>
###xml 231 239 <span type="species:ncbi:9606">patients</span>
###xml 634 642 <span type="species:ncbi:9606">patients</span>
###xml 1182 1186 <span type="species:ncbi:10090">mice</span>
Given the complexity of glaucoma, multiple different mechanisms are likely to contribute to disease in individual patients [3,58,60]. The relative importance of specific pathogenic mechanisms is likely to differ between individual patients and individual eyes due to differences in magnitude or duration of IOP elevation, environment, lifestyle or genetic constitution. Moreover, it is possible that different RGCs degenerate by different mechanisms even within an individual eye, depending on differences in protective or damaging factors in the local microenvironment. Mild or transient ischemia may contribute to RGC death in some patients [reviewed in [61-63]]. Thus, although we found no protective effect of NOS2 in the inherited DBA/2J model of glaucoma, it will be important to study the role of NOS2 in settings that have a greater ischemic component. Both IOP and blood pressure determine ocular perfusion pressure, and decreased ocular perfusion pressure may contribute to glaucomatous damage [64,65]. Thus, individuals with low blood pressure may be at greater risk of glaucomatous damage and their glaucoma may have a relatively strong ischemic component. Using DBA/2J mice, our future studies will assess these possibilities, including the potential protective role of NOS2 in a low blood pressure setting.
###end p 40
###begin p 41
###xml 263 268 263 268 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS2 </italic>
###xml 325 327 325 327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B66">66</xref>
###xml 366 371 366 371 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS2 </italic>
###xml 403 405 403 405 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B67">67</xref>
###xml 19 24 <span type="species:ncbi:9606">human</span>
###xml 476 483 <span type="species:ncbi:9606">patient</span>
###xml 627 632 <span type="species:ncbi:9606">human</span>
Genetic studies of human glaucoma have identified glaucoma genes and potential alleles that confer increased risk of disease. These genetic studies will help to define key pathologic mechanisms. One study reported a correlation between a regulatory region of the NOS2 gene and the development of primary open angle glaucoma [66]. However, in another study where the NOS2 gene was specifically assessed [67], NOS2 was not found to be associated with glaucoma. Studies of large patient populations are needed to exploit the full benefit of genetic studies for glaucoma. Continued studies utilizing a variety of animal models and human samples are clearly required to resolve the complex molecular pathways that determine RGC survival and death in glaucoma.
###end p 41
###begin title 42
Conclusion
###end title 42
###begin p 43
###xml 158 163 158 163 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nos2 </italic>
###xml 87 91 <span type="species:ncbi:10090">mice</span>
NOS2 activity is not required for RGC death and associated axon degeneration in DBA/2J mice. Further studies are required to assess the general importance of Nos2 in glaucoma.
###end p 43
###begin title 44
Methods
###end title 44
###begin title 45
Animal Husbandry
###end title 45
###begin p 46
###xml 534 538 528 532 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nos2</italic>
###xml 540 544 534 538 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nos2</italic>
###xml 544 546 538 540 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tm</italic>
###xml 547 551 541 545 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lau </italic>
###xml 544 551 538 545 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>tm</italic>1<italic>Lau </italic></sup>
###xml 552 554 546 548 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 127 131 <span type="species:ncbi:10090">mice</span>
###xml 236 240 <span type="species:ncbi:10090">mice</span>
###xml 675 679 <span type="species:ncbi:10090">mice</span>
###xml 759 763 <span type="species:ncbi:10090">mice</span>
###xml 871 875 <span type="species:ncbi:10090">mice</span>
All experiments were performed in compliance with the ARVO statement for use of animals in ophthalmic and vision research. All mice were bred at the Jackson Laboratory and maintained at The Jackson Laboratory or Alcon Laboratories. The mice were fed NIH31 (6% fat) chow ad libitum, and their water was acidified to pH 2.8 to 3.2. The environment was kept at 21degreesC with a 14 hour light: 10 hour dark cycle. The colony was monitored for specific pathogens by The Jackson Laboratory's routine surveillance program. A null allele of Nos2, Nos2tm1Lau [48], was backcrossed into DBA/2J for at least 13 generations. In the experiments using the null allele, only female DBA/2J mice were used. Furthermore, heterozygous by heterozygous matings were used so that mice of each genotype were littermates. Using this scheme protects from litter or cage-dependent differences as mice of each genotypes are housed together.
###end p 46
###begin title 47
Quantitative Real Time PCR
###end title 47
###begin p 48
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nos2 </italic>
###xml 629 634 629 634 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nos2 </italic>
###xml 717 723 717 723 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Gstm5 </italic>
###xml 772 778 772 778 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pias1 </italic>
###xml 830 836 830 836 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Socs4 </italic>
###xml 1274 1278 1270 1274 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nos2</italic>
###xml 1321 1326 1317 1322 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Gstm5</italic>
###xml 1327 1332 1323 1328 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pias1</italic>
###xml 1333 1338 1329 1334 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Socs4</italic>
###xml 80 84 <span type="species:ncbi:10090">mice</span>
###xml 224 228 <span type="species:ncbi:10090">mice</span>
Nos2 RNA expression levels were assessed in 25 eyes from 10.5 months old DBA/2J mice (10 no or early, 6 moderate and 9 severe glaucoma - see optic nerve damage assessment) along with 10 'control' eyes from 4.5 months DBA/2J mice (pre-glaucoma). The front of each eye and lens were removed and the optic nerve head region dissected free using a sharpened 1 mm glass capillary. The ONH tissue was placed in RNAlater (Qiagen) for at least 24 hours then RNA was isolated using Microkit RNA extraction (Qiagen). For each eye, 35 ng of RNA was used to generate first strand cDNA using Message Sensor RT (Ambion). Expression levels for Nos2 (using primers GTCATGGCTTCACGGGTCAG and CCAGGTCCCTGGCTAGTGCT) and 3 control genes, Gstm5 (TCCTGCAGTCTGACCGCTTC and GCGAGCTCTGGCTCAGCATA), Pias1 (CATCTCTGCCAGCCACCAAC and TGGCCATGGCTCTCTCTCAG) and Socs4 (ACGTCCACTGCCTTGTTCCA and AGCAGAGCTTCGGCTGCATA) were determined for each eye. The 3 control genes were selected as they had the most consistent expression among 194 tested genes, irrespective of damage level (data not shown). Real time PCR reactions were prepared using Quant-iT Ribogreen RNA assay kit (Invitrogen) and run on the 7900 HT Fast Real Time PCR system (Applied Biosystems). For each eye, DeltaCT values were calculated as CT(Nos2) - Geometric Mean of CTs for normalizers (Gstm5/Pias1/Socs4). The average of 'control' eyes was calculated and relative expression values for each of the 'sample' eyes was calculated as DeltaCT (sample)/DeltaCT (pre-glaucoma average). Finally, the average relative expression values and standard errors of the mean for each of the no or early, moderate and pre-glaucoma categories were calculated. Significance was assessed using Chi squared analysis (JMP 6.0.3)
###end p 48
###begin title 49
Immunohistochemistry
###end title 49
###begin p 50
###xml 348 354 <span type="species:ncbi:9986">rabbit</span>
###xml 396 402 <span type="species:ncbi:9986">rabbit</span>
###xml 713 717 <span type="species:ncbi:10090">mice</span>
Whole eyes were immersion fixed in 4% paraformaldehyde in 1 x phosphate buffer for 24 hours at 4degreesC. Tissue was then either immediately processed and embedded in paraffin or was stored at 4degreesC in 0.4% paraformaldehyde in phosphate buffer. 8 mum paraffin sections were cut and processed for immunohistochemistry. NOS2 was visualized using rabbit anti-NOS2 (Santa Cruz, 1:200), with anti rabbit-Alexa 594 (Molecular Probes, 1;1000) as secondary. DAPI (Sigma) was used as a nuclear stain. Images were captured using Metamorph imaging software (Version 4.6, Universal Imaging, Downingtown, PA). All images were further processed with Adobe Photoshop and treated identically. As a positive control for NOS2, mice were treated with lipopolysaccahride (LPS), which is known to up-regulate NOS2 in the kidney. Eight hours after a single intraperitoneal injection of LPS (10 mg/kg) kidneys were harvested, processed and stained as described for eyes.
###end p 50
###begin title 51
Aminoguanidine Treatment
###end title 51
###begin p 52
###xml 4 8 <span type="species:ncbi:10090">mice</span>
###xml 301 305 <span type="species:ncbi:10090">mice</span>
###xml 329 333 <span type="species:ncbi:10090">mice</span>
###xml 500 504 <span type="species:ncbi:10090">mice</span>
For mice in the aminoguanidine treatment group, 1 mg/ml of aminoguanidine was added to their drinking water. Treated and untreated water was changed on the same schedule (2 times a week). Treatment began at 2 months of age for the 3.5 months cohort and at 3 or 5 months of age for the 9-12 months old mice. Treated and untreated mice could not be in the same cage, but their cages were intermixed on the same shelves in the animal room and handled similarly. Roughly equal numbers of male and female mice were used for the 3.5 and 10-12 months old age groups. Significance was assessed using Chi squared analysis (JMP 6.0.3)
###end p 52
###begin title 53
Iris Disease and Intraocular Pressure Measurement
###end title 53
###begin p 54
###xml 222 224 222 224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 225 227 225 227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 228 230 228 230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 231 233 231 233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B68">68</xref>
###xml 312 314 312 314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B69">69</xref>
###xml 315 317 315 317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B71">71</xref>
###xml 71 76 <span type="species:ncbi:10090">mouse</span>
###xml 193 197 <span type="species:ncbi:10090">mice</span>
The experimenter was unaware of the genotype or treatment group of the mouse at time of the examination. A slit-lamp bio-microscope was used to track the iris disease that is present in DBA/2J mice as previously reported [37,39,40,68]. The microneedle method of IOP measurement was used as previously described [69-71]. Ages and sample sizes are detailed in the results. Statistical analysis was by ANOVA.
###end p 54
###begin title 55
Optic Nerve Damage Assessment
###end title 55
###begin p 56
###xml 109 111 109 111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 112 114 112 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 115 117 115 117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B72">72</xref>
###xml 933 935 933 935 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 936 938 936 938 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B73">73</xref>
###xml 1257 1261 <span type="species:ncbi:10090">mice</span>
###xml 1587 1591 <span type="species:ncbi:10090">mice</span>
Retro-orbital optic nerves were fixed, processed, embedded in plastic, and sectioned as previously reported [40,42,72]. Sections were stained with paraphenylenediamine (PPD), which stains all myelin sheaths, but differentially stains the axoplasm of sick or dying axons darkly. This method is more sensitive at detecting glaucomatous damage than axon counting. This is because individual damaged axons can be detected by PPD staining while substantial axon loss is necessary to detect differences when comparing axon counts (due to the considerable variability in axon number from eye to eye). The 362 optic nerves used in this study were independently determined to have either no or early, moderate, or severe glaucomatous damage by multiple masked investigators (see below). Axon counts on randomly selected nerves with each damage level have demonstrated that each assigned level represents a clearly separable stage of disease [42,73]. To assign a damage level, the investigators analyzed each nerve for the relative number of healthy and damaged axons as well as the amount of gliosis. In nerves with no or early glaucoma fewer than 2% of the axons are lost or damaged. This mild level of damage is routinely observed in aged-matched non-glaucomatous mice and so we have previously called this damage level mild but not considered it a definitive stage of glaucoma. Some of these eyes must be at early stages of glaucoma that are not detectable by these methods while others have no glaucoma. Thus, we have reclassified this damage level as no or early glaucoma when studying aged mice. Nerves with no or early glaucoma have 51195 +/- 934 (mean +/- SEM, n = 18) axons and are not statistically different from young pre-glaucomatous DBA/2J nerves 52074 +/- 451 (p > 0.05) (n = 10). Moderately affected nerves have numerous sick and degenerating axons throughout the nerve, but the majority of axons appear healthy. Nerves with this level of damage have typically lost approximately 30% of their axons and on average have 31410 +/- 2199 (n = 8) axons remaining. Severe nerves have lost more than 50% of their axons, and many severe nerves have lost the vast majority of their axons(5454 +/- 1211, n = 24). Of the 390 nerves used in this study, the first two investigators assigned the same damage level 87% of the time. If the two investigators did not assign the same damage level, a third masked investigator graded the nerve. The first two investigators never differed by more than one damage level and the damage level determined by the third investigators always matched that of one of the first two investigators. The final damage level was assigned by consensus (the most common damage level assigned). The nerve damage distributions of the different genotypes or treatment groups were compared by Chi square analysis (JMP 6.0.3).
###end p 56
###begin title 57
Retinal Flat Mounts
###end title 57
###begin p 58
###xml 87 89 87 89 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
Retinal flat mounts were prepared and RGC layer cells counted as previously described [42]. Briefly, eyes were removed and fixed overnight at 4degreesC in 4% paraformaldehyde in 1 x phosphate buffer. After fixation eyes were rinsed, processed and flat-mounted onto a microscope slide with the RGC layer face up. The RGC layer was stained with a modified Nissl stain. Eight 40x fields, consisting of two fields from the periphery of each retinal quadrant were electronically photographed and counted (manually) using Metamorph software. The sum of all eight fields was used for the total for each retina. Age matched retinas with corresponding optic nerves that had no signs of glaucomatous damage were used as controls for the glaucomatous retinas. Significance (P < 0.05) was determined using the student's t test.
###end p 58
###begin title 59
Authors' contributions
###end title 59
###begin p 60
###xml 259 263 <span type="species:ncbi:10090">mice</span>
SWMJ and AFC conceived the study and oversaw all components including manuscript preparation. RTL, GRH, IHP, SWMJ and AFC participated in the design of the experiments and the analysis of data. RTL, GRH and SWMJ wrote the manuscript. SWMJ and IHP treated the mice with aminoguanidine and OVS participated in IOP and tissue collection. AM performed real time PCR and participated in analysis of data. JB performed RGC layer counts and participated in analysis of data. RSS performed clinical analyses and participated in assessing optic nerve damage levels. All authors read and approved the final manuscript.
###end p 60
###begin title 61
Acknowledgements
###end title 61
###begin p 62
###xml 106 110 106 110 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nos2</italic>
The authors would like to acknowledge Oliver Smithies and Edward Shesely for providing the null allele of Nos2. We thank L. Wilson, A. Bell, I. M. Cosma, P.E. Hellberg for technical assistance with the experiments, and J. Torrance for figure preparation. We also thank The Jackson Laboratory Scientific Services including P. Finger, J. Miller and B. Mortimer for technical assistance. Scientific support services are subsidized by a core grant from the National Cancer Institute (CA34196). SWMJ is an Investigator of the Howard Hughes Medical Institute.
###end p 62
###begin article-title 63
###xml 14 20 <span type="species:ncbi:9606">people</span>
The number of people with glaucoma worldwide in 2010 and 2020
###end article-title 63
###begin article-title 64
###xml 10 16 <span type="species:ncbi:9606">people</span>
Number of people with glaucoma worldwide
###end article-title 64
###begin article-title 65
Complex genetics of glaucoma susceptibility
###end article-title 65
###begin article-title 66
The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma
###end article-title 66
###begin article-title 67
Glaucoma: macrocosm to microcosm the Friedenwald lecture
###end article-title 67
###begin article-title 68
Relationship between intraocular pressure and primary open angle glaucoma among white and black Americans. The Baltimore Eye Survey
###end article-title 68
###begin article-title 69
The epidemiology of open-angle glaucoma: a review
###end article-title 69
###begin article-title 70
Risk factors for open-angle glaucoma. The Barbados Eye Study
###end article-title 70
###begin article-title 71
Biostatistical analysis of the collaborative glaucoma study. I. Summary report of the risk factors for glaucomatous visual-field defects
###end article-title 71
###begin article-title 72
Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial
###end article-title 72
###begin article-title 73
The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma
###end article-title 73
###begin article-title 74
7. The relationship between control of intraocular pressure and visual field deterioration
###end article-title 74
###begin article-title 75
Inflammatory neurodegeneration mediated by nitric oxide, glutamate, and mitochondria
###end article-title 75
###begin article-title 76
Nitric oxide in neurodegeneration
###end article-title 76
###begin article-title 77
Inducible nitric oxide synthase mediates retinal apoptosis in ischemic proliferative retinopathy
###end article-title 77
###begin article-title 78
Loss of retinal ganglion cells following retinal ischemia: the role of inducible nitric oxide synthase
###end article-title 78
###begin article-title 79
Inducible nitric oxide synthase in retinal ischemia-reperfusion injury
###end article-title 79
###begin article-title 80
###xml 41 44 <span type="species:ncbi:10116">rat</span>
Nitric oxide synthase inhibitors protect rat retina against ischemic injury
###end article-title 80
###begin article-title 81
Nitric oxide synthase inhibition delays axonal degeneration and promotes the survival of axotomized retinal ganglion cells
###end article-title 81
###begin article-title 82
###xml 27 32 <span type="species:ncbi:9606">human</span>
Activated microglia in the human glaucomatous optic nerve head
###end article-title 82
###begin article-title 83
###xml 29 34 <span type="species:ncbi:9606">human</span>
Nitric oxide synthase in the human glaucomatous optic nerve head
###end article-title 83
###begin article-title 84
###xml 76 81 <span type="species:ncbi:9606">human</span>
Expression of nitric oxide synthase-2 (NOS-2) in reactive astrocytes of the human glaucomatous optic nerve head
###end article-title 84
###begin article-title 85
Glaucoma: thinking in new ways-a role for autonomous axonal self-destruction and other compartmentalised processes?
###end article-title 85
###begin article-title 86
Chronic glaucoma selectively damages large optic nerve fibers
###end article-title 86
###begin article-title 87
Retinal ganglion cell death in experimental glaucoma and after axotomy occurs by apoptosis
###end article-title 87
###begin article-title 88
Chronic experimental glaucoma in primates. II. Effect of extended intraocular pressure elevation on optic nerve head and axonal transport
###end article-title 88
###begin article-title 89
Neuronal death in glaucoma
###end article-title 89
###begin article-title 90
###xml 87 91 <span type="species:ncbi:10090">mice</span>
Retinal ganglion cell degeneration is topological but not cell type specific in DBA/2J mice
###end article-title 90
###begin article-title 91
Effect of intraocular pressure on rapid axoplasmic transport in monkey optic nerve
###end article-title 91
###begin article-title 92
###xml 99 103 <span type="species:ncbi:10116">rats</span>
Retrograde axonal transport of BDNF in retinal ganglion cells is blocked by acute IOP elevation in rats
###end article-title 92
###begin article-title 93
###xml 27 32 <span type="species:ncbi:9606">human</span>
Nitric oxide synthase-2 in human optic nerve head astrocytes induced by elevated pressure in vitro
###end article-title 93
###begin article-title 94
###xml 57 60 <span type="species:ncbi:10116">rat</span>
Isoforms of nitric oxide synthase in the optic nerves of rat eyes with chronic moderately elevated intraocular pressure
###end article-title 94
###begin article-title 95
###xml 96 99 <span type="species:ncbi:10116">rat</span>
A prodrug of a selective inhibitor of inducible nitric oxide synthase is neuroprotective in the rat model of glaucoma
###end article-title 95
###begin article-title 96
Nitric oxide: a potential mediator of retinal ganglion cell damage in glaucoma
###end article-title 96
###begin article-title 97
Evaluation of inducible nitric oxide synthase in glaucomatous optic neuropathy and pressure-induced optic nerve damage
###end article-title 97
###begin article-title 98
###xml 118 121 <span type="species:ncbi:10116">Rat</span>
Oral Administration of SC-51, a Nitric Oxide Synthase Inhibitor, Does Not Protect Optic Nerve Axons in a Hypertensive Rat Model of Glaucoma
###end article-title 98
###begin article-title 99
###xml 66 70 <span type="species:ncbi:10090">mice</span>
Interacting loci cause severe iris atrophy and glaucoma in DBA/2J mice
###end article-title 99
###begin article-title 100
###xml 85 89 <span type="species:ncbi:10090">mice</span>
Mutations in genes encoding melanosomal proteins cause pigmentary glaucoma in DBA/2J mice
###end article-title 100
###begin article-title 101
###xml 67 71 <span type="species:ncbi:10090">mice</span>
Essential iris atrophy, pigment dispersion, and glaucoma in DBA/2J mice
###end article-title 101
###begin article-title 102
###xml 29 33 <span type="species:ncbi:10090">mice</span>
Inherited glaucoma in DBA/2J mice: pertinent disease features for studying the neurodegeneration
###end article-title 102
###begin article-title 103
Mechanistic insights into glaucoma provided by experimental genetics the cogan lecture
###end article-title 103
###begin article-title 104
Susceptibility to neurodegeneration in a glaucoma is modified by Bax gene dosage
###end article-title 104
###begin article-title 105
###xml 70 74 <span type="species:ncbi:10090">mice</span>
Progressive ganglion cell loss and optic nerve degeneration in DBA/2J mice is variable and asymmetric
###end article-title 105
###begin article-title 106
###xml 90 94 <span type="species:ncbi:10090">mice</span>
###xml 138 142 <span type="species:ncbi:10090">mice</span>
Quantitative analysis of retinal ganglion cell (RGC) loss in aging DBA/2NNia glaucomatous mice: comparison with RGC loss in aging C57/BL6 mice
###end article-title 106
###begin article-title 107
Axons of retinal ganglion cells are insulted in the optic nerve early in DBA/2J glaucoma
###end article-title 107
###begin article-title 108
###xml 42 47 <span type="species:ncbi:10090">mouse</span>
Optic nerve degeneration in the DBA/2NNia mouse: is the lamina cribrosa important in the development of glaucomatous optic neuropathy?
###end article-title 108
###begin article-title 109
Effect of ocular hypertension on retinal nitridergic pathway activity
###end article-title 109
###begin article-title 110
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice lacking inducible nitric oxide synthase are not resistant to lipopolysaccharide-induced death
###end article-title 110
###begin article-title 111
###xml 81 86 <span type="species:ncbi:10090">mouse</span>
Genetic context determines susceptibility to intraocular pressure elevation in a mouse pigmentary glaucoma
###end article-title 111
###begin article-title 112
###xml 72 78 72 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Gpnmb </italic>
###xml 82 87 82 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tyrp1</italic>
###xml 30 34 <span type="species:ncbi:10090">mice</span>
Absence of glaucoma in DBA/2J mice homozygous for wild-type versions of Gpnmb and Tyrp1
###end article-title 112
###begin article-title 113
###xml 112 115 <span type="species:ncbi:10116">rat</span>
Inhibition of nitric-oxide synthase 2 by aminoguanidine provides neuroprotection of retinal ganglion cells in a rat model of chronic glaucoma
###end article-title 113
###begin article-title 114
###xml 40 45 <span type="species:ncbi:10090">mouse</span>
Retinal neurodegeneration in the DBA/2J mouse-a model for ocular hypertension
###end article-title 114
###begin article-title 115
###xml 50 55 <span type="species:ncbi:10090">mouse</span>
Cardiovascular and renal control in NOS-deficient mouse models
###end article-title 115
###begin article-title 116
###xml 95 100 <span type="species:ncbi:9606">human</span>
Activation of epidermal growth factor receptor signals induction of nitric oxide synthase-2 in human optic nerve head astrocytes in glaucomatous optic neuropathy
###end article-title 116
###begin article-title 117
Comparison of the signal transduction pathways for the induction of gene expression of nitric oxide synthase-2 in response to two different stimuli
###end article-title 117
###begin article-title 118
Pharmacologic neuroprotection with an inhibitor of nitric oxide synthase for the treatment of glaucoma
###end article-title 118
###begin article-title 119
###xml 2 5 <span type="species:ncbi:10116">rat</span>
A rat model of chronic pressure-induced optic nerve damage
###end article-title 119
###begin article-title 120
Understanding mechanisms of pressure-induced optic nerve damage
###end article-title 120
###begin article-title 121
Prospects for relevant glaucoma models with retinal ganglion cell damage in the rodent eye
###end article-title 121
###begin article-title 122
Risk factors and open-angle glaucoma: classification and application
###end article-title 122
###begin article-title 123
Optic nerve oxygenation
###end article-title 123
###begin article-title 124
Introductory comments on blood flow autoregulation in the optic nerve head and vascular risk factors in glaucoma
###end article-title 124
###begin article-title 125
Is Ischemia the villain in glaucomatous cupping and atrophy?
###end article-title 125
###begin article-title 126
Blood pressure, arterial stiffness, and open-angle glaucoma: the Rotterdam study
###end article-title 126
###begin article-title 127
Risk Factors for Incident Open-angle Glaucoma The Barbados Eye Studies
###end article-title 127
###begin article-title 128
The promoter of inducible nitric oxide synthase implicated in glaucoma based on genetic analysis and nuclear factor binding
###end article-title 128
###begin article-title 129
Evidence for association of endothelial nitric oxide synthase gene in subjects with glaucoma and a history of migraine
###end article-title 129
###begin article-title 130
By altering ocular immune privilege, bone marrow-derived cells pathogenically contribute to DBA/2J pigmentary glaucoma
###end article-title 130
###begin article-title 131
###xml 45 49 <span type="species:ncbi:10090">mice</span>
Intraocular pressure in genetically distinct mice: an update and strain survey
###end article-title 131
###begin article-title 132
###xml 36 40 <span type="species:ncbi:10090">Mice</span>
Intraocular Pressure Measurement in Mice:Technical Aspects
###end article-title 132
###begin article-title 133
###xml 31 36 <span type="species:ncbi:10090">mouse</span>
Intraocular pressure in inbred mouse strains
###end article-title 133
###begin article-title 134
General and Special Histopathology
###end article-title 134
###begin article-title 135
High-dose radiation with bone marrow transfer prevents neurodegeneration in an inherited glaucoma
###end article-title 135

